{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:06:55Z","timestamp":1774040815459,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.10.058","type":"journal-article","created":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T17:57:33Z","timestamp":1604253453000},"page":"7949-7955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures"],"prefix":"10.1016","volume":"38","author":[{"given":"Mathias","family":"Mangion","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-5781","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"G\u00e9linas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahita","family":"Bakhshi Zadeh Gashti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiva","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Kiesslich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasha","family":"Nassoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parminder S","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Kobinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9nald","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Gaillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-8815","authenticated-orcid":false,"given":"Amine","family":"Kamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.10.058_b0005","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 2020 fact sheet 2020. https:\/\/www.unaids.org\/en\/resources\/fact-sheet (accessed July 30, 2020)."},{"key":"10.1016\/j.vaccine.2020.10.058_b0010","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0140-6736(19)32682-0","article-title":"The complex challenges of HIV vaccine development require renewed and expanded global commitment","volume":"395","author":"Bekker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.10.058_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107214","article-title":"Potential future impact of a partially effective HIV vaccine in a southern African setting","volume":"9","author":"Phillips","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.10.058_b0020","first-page":"313","article-title":"Vesicular stomatitis and its relation to the diagnosis of foot-and-mouth disease","volume":"69","author":"Cotton","year":"1926","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2020.10.058_b0025","first-page":"757","article-title":"Human infection with the virus of vesicular stomatitis","volume":"36","author":"Hanson","year":"1950","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.vaccine.2020.10.058_b0030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4269\/ajtmh.1966.15.244","article-title":"Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV)","volume":"15","author":"Johnson","year":"1966","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.10.058_b0035","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1128\/JVI.78.10.5458-5465.2004","article-title":"Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0040","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(19)32905-8","article-title":"Ebola virus vaccine receives prequalification","volume":"394","author":"Burki","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.10.058_b0045","doi-asserted-by":"crossref","first-page":"10194","DOI":"10.1128\/JVI.74.21.10194-10201.2000","article-title":"Functional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein","volume":"74","author":"Watanabe","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0050","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe","volume":"347","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.058_b0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A Recombinant Vesicular Stomatitis Virus Ebola Vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.058_b0060","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: A randomized clinical trial","volume":"189","author":"ElSherif","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2020.10.058_b0065","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u0394G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.058_b0070","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.058_b0075","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV\u0394G-ZEBOV-GP Vaccine Tolerability and Safety during the West Africa Ebola Outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.058_b0080","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.10.058_b0085","unstructured":"World Health Organisation. Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic respons 2019. (accessed July 30, 2020). https:\/\/reliefweb.int\/sites\/reliefweb.int\/files\/resources\/ebola-ring-vaccination-results-12-april-2019.pdf."},{"key":"10.1016\/j.vaccine.2020.10.058_b0090","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12981-017-0179-2","article-title":"Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses","volume":"14","author":"Racine","year":"2017","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.vaccine.2020.10.058_b0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00281-006-0042-3","article-title":"Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector","volume":"28","author":"Clarke","year":"2006","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106597","article-title":"A novel, live-attenuated vesicular stomatitis virus vector displaying conformationally intact, functional HIV-1 envelope trimers that elicits potent cellular and humoral responses in mice","volume":"9","author":"Rabinovich","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.10.058_b0105","doi-asserted-by":"crossref","DOI":"10.1097\/01.qai.0000513860.96393.07","article-title":"Mucosal vaccination with a replication-competent VSV-HIV chimera delivering Env trimers protects rhesus macaques from rectal SHIV infection","volume":"74","author":"Parks","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2020.10.058_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/aid.2016.5000.abstracts","article-title":"Abstracts of the HIV Research for Prevention Meeting, HIVR4P, 17\u201320 October, 2016, Chicago, USA","volume":"32","author":"Parks","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2020.10.058_b0115","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nature04817","article-title":"Distribution and three-dimensional structure of AIDS virus envelope spikes","volume":"441","author":"Zhu","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.10.058_b0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12981-017-0179-2","article-title":"Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses","volume":"14","author":"Racine","year":"2017","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.vaccine.2020.10.058_b0125","doi-asserted-by":"crossref","first-page":"15812","DOI":"10.1073\/pnas.2634931100","article-title":"Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions","volume":"100","author":"Zhu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2020.10.058_b0130","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1016\/j.vaccine.2019.09.044","article-title":"Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells","volume":"37","author":"G\u00e9linas","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.058_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2020.107608","article-title":"Vero cell upstream bioprocess development for the production of viral vectors and vaccines","volume":"44","author":"Kiesslich","year":"2020","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2020.10.058_b0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0145","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/JVI.01863-12","article-title":"HIV-1 Resistance to Maraviroc Conferred by a CD4 Binding Site Mutation in the Envelope Glycoprotein gp120","volume":"87","author":"Ratcliff","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0150","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0155","article-title":"Titration methods for rVSV-based vaccine manufacturing","author":"G\u00e9linas","year":"20207","journal-title":"MethodsX"},{"key":"10.1016\/j.vaccine.2020.10.058_b0160","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/JVI.02297-12","article-title":"Antigenicity and Immunogenicity of Transmitted\/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1","volume":"87","author":"Liao","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0165","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.immuni.2012.11.011","article-title":"Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2020.10.058_b0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jbiotec.2018.11.023","article-title":"Optimization of Production of Vesicular Stomatitis Virus (VSV) in suspension serum-free culture medium at high cell density","volume":"289","author":"Elahi","year":"2019","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jbiotec.2020.01.015","article-title":"Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X TM hydro fixed-bed","volume":"310","author":"Kiesslich","year":"2020","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0180","article-title":"Development, manufacturing, and supply of MSD\u2019s Ebola vaccine","author":"Blue","year":"2016","journal-title":"Vaccine Technol VI Albufeira Port"},{"key":"10.1016\/j.vaccine.2020.10.058_b0185","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1128\/jb.68.6.724-726.1954","article-title":"Morphology of vesicular stomatitis virus","volume":"68","author":"Chow","year":"1954","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2020.10.058_b0190","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0042-6822(62)90228-3","article-title":"The development and structure of vesicular stomatitis virus","volume":"16","author":"Howatson","year":"1962","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:49:43Z","timestamp":1759402183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20313670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":38,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20313670"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of novel HIV vaccine candidates using recombinant vesicular stomatitis virus vector produced in serum-free Vero cell cultures","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}